← Leaderboards
Tomoo Iwakuma
Tulane University Of Louisiana
$5,211,581
Attributed
$5,211,581
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $663.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,211,581 · 9
By mechanism
R01$3,893,354 · 3
P20$1,303,227 · 5
R13$15,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorIn VivoMalignant NeoplasmsPathway InteractionsProteinsPlayAffectTp53 GeneBaseMutateMouse ModelOverexpressionKnock-OutOsteosarcomaBinding ProteinsOutcome ForecastTumor ProgressionMutantNeoplasm MetastasisCellsAttenuatedAllelesMolecularInhibitor/Antagonist
Grant awards (17)
Simultaneous ROS production and DDR inhibition to trigger p53 synthetic lethality$560,458
R01 · FY2025 · CA · contact PI
The 10th International MDM2 Workshop$15,000
R13 · FY2023 · CA · contact PI
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis$342,790
R01 · FY2022 · CA · contact PI
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis$384,018
R01 · FY2021 · CA · contact PI
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis$349,988
R01 · FY2020 · CA · contact PI
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis$339,487
R01 · FY2019 · CA · contact PI
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis$349,988
R01 · FY2018 · CA · contact PI
The role of MDM2-MTBP axis in cancer metastasis$313,325
R01 · FY2018 · CA · contact PI
The role of MDM2-MTBP axis in cancer metastasis$313,325
R01 · FY2017 · CA · contact PI
The role of MDM2-MTBP axis in cancer metastasis$313,325
R01 · FY2016 · CA · contact PI
The role of MDM2-MTBP axis in cancer metastasis$313,325
R01 · FY2015 · CA · contact PI
The role of MDM2-MTBP axis in cancer metastasis$313,325
R01 · FY2014 · CA · contact PI
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP$223,456
P20 · FY2011 · RR · contact PI
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP$177,347
P20 · FY2010 · RR · contact PI
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS$220,991
P20 · FY2009 · RR · contact PI
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS$346,252
P20 · FY2008 · RR · contact PI
DISSECTING ROLES OF MTBP IN OSTEOSARCOMA METASTASIS$335,181
P20 · FY2007 · RR · contact PI